Fate Therapeutics, Inc.FATENASDAQ
LOADING
|||
Net Income Growth Under Pressure
Trending lower, above historical average.
Left:
||||
Year-over-year net income growth rate
Latest
5.34%
↑ 157% above average
Average (39q)
-9.29%
Historical baseline
Range
High:66.50%
Low:-179.41%
CAGR
NaN%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | 5.34% |
| Q2 2025 | 9.44% |
| Q1 2025 | 27.86% |
| Q4 2024 | -9.39% |
| Q3 2024 | -24.07% |
| Q2 2024 | 19.95% |
| Q1 2024 | -8.80% |
| Q4 2023 | 2.32% |
| Q3 2023 | 14.38% |
| Q2 2023 | -179.41% |
| Q1 2023 | 66.50% |
| Q4 2022 | 32.55% |
| Q3 2022 | -9.80% |
| Q2 2022 | -15.85% |
| Q1 2022 | 4.27% |
| Q4 2021 | -58.45% |
| Q3 2021 | 21.45% |
| Q2 2021 | -22.28% |
| Q1 2021 | 15.10% |
| Q4 2020 | 9.50% |
| Q3 2020 | -109.05% |
| Q2 2020 | 16.25% |
| Q1 2020 | -18.44% |
| Q4 2019 | -6.36% |
| Q3 2019 | -13.34% |
| Q2 2019 | -18.82% |
| Q1 2019 | -23.29% |
| Q4 2018 | 4.50% |
| Q3 2018 | 14.61% |
| Q2 2018 | -39.04% |
| Q1 2018 | -13.11% |
| Q4 2017 | -16.97% |
| Q3 2017 | -10.77% |
| Q2 2017 | 4.75% |
| Q1 2017 | -27.53% |
| Q4 2016 | 9.12% |
| Q3 2016 | -3.91% |
| Q2 2016 | -0.37% |
| Q1 2016 | -12.50% |
| Q4 2015 | -8.13% |